QC vi­o­la­tions raised by FDA at an­oth­er Au­robindo site

Gener­ic drug man­u­fac­tur­er Au­robindo Phar­ma has re­ceived an­oth­er 483 in­spec­tion re­port from the FDA, this time with qual­i­ty con­cerns, par­tic­u­lar­ly in re­sponse to cus­tomer com­plaints …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER